🔗 Share this article

Given that America undertakes unprecedented revisions to its vaccine schedules, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about Covid vaccines during the global health crisis and has zeroed in on potential deaths following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Program

Health officials planned to reveal radical revisions to the childhood vaccine schedule recently, bringing the US with Denmark’s national calendar, sources say – a significant shift that would place the US at odds with much of the global community with little proof for benefit. The planned update has been delayed until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to address the audience at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to lead the division this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting specific childhood vaccine recommendations in the US in order to be more like the Danish model, a society with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial comments, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Expertise

The appointee has no obvious track record in pharmaceutical research, oversight or administrative roles, which has been customary for past directors of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for leading the CDER, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a large organization. She has no expertise in pharmaceutical oversight.”

Previous directors of CBER would “grasp legal statutes and the research of drug development”, noted Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who headed the center have had.”

CDER has an immense workload at the agency, she stated.

“The public just zeroes in on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these need to be looked after,” she explained. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant administrative aspect to the position, which oversees more than 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” she added.

Agency Reaction and Disputed Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries stem from incorrect premises”.

“This background is consistent with the duties of her position,” the official stated, pointing to the time Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s controversial priority voucher program, a disputed one-day medication authorization process that allegedly troubled her former heads. “How are these therapies being selected for this voucher program? Who is making the choices?” Dr. Howard said. “There’s a lot of secrecy happening at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards laxer rules of all drugs, with the exception of shots.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if troubling, history, Howard said. She authored a analysis using non-validated crowd-sourced reports to determine the rate of myocarditis after COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the new federal leadership featured altering regulations for novel immunizations and ending “optional” vaccines, she said post-election on a podcast. At the FDA, Høeg has allegedly proposed preventing young men from receiving COVID-19 vaccinations.

“She’s an all-around ideologue who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a extremely misleading, dishonest manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|